1、该刊只有国际刊号。

2、投稿方式：在线投稿。

3、官网网址（微信公众号信息）：

https://www.the-innovation.org/the-innovation-drug-discovery

4、投稿系统：

https://mc03.manuscriptcentral.com/innovation-drugdisc

5、官网邮箱：drugdiscovery@the-innovation.org

6、出刊日期：季刊，一年出版四期。

7、官方微信公众号：TheInnovation创新

8、官网信息：2027年12月31日前投稿不收文章处理费。

2026年4月23日星期四

For Authors

【官网信息】

Information for Authors

The

Innovation Drug Discovery is a joint publication of The Innovation and

Chengdu University of Traditional Chinese Medicine. As a sister journal

of The Innovation, The Innovation Drug Discovery highlights the most

groundbreaking scientific breakthroughs in drug research and

development, aiming to bridge the gap in multidisciplinary integration,

establish a leading academic platform that promotes global drug

discovery and accelerates the development of new therapeutic approaches.

The Innovation Drug Discovery aims to become a leading scholarly

publication, achieve Zone 1 classification according to the Chinese

Academy of Sciences standards, and serve as the premier platform for

disseminating pivotal research findings.After publishing, your works

will go to global reach and visibility, which is supposed to educate

this journal's audience.

The official abbreviation of The Innovation Drug Discovery is "Innov. Drug Discov.".

Aims & Scope

The

Innovation Drug Discovery is an international, open-access journal that

publishes innovative, rigorous, and impactful research covering the

entire drug discovery and development process, as well as content

addressing significant themes relevant to the drug discovery and

development arena, including but not limited to:

1. Target discovery and validation

2. Rational drug design and drug information

3. Therapeutic targets

4.Small molecules & medicinal chemistry

5. Novel therapeutic strategies

6. Natural products

7. Drug delivery

8. High-throughput screening

9. Preclinical & early phase clinical studies

10. Biopharmaceuticals & large molecules

11. Clinical trials

12. Special drugs

13. AI-assisted de novo drug design

14. Radiopharmaceuticals

Editorial Policies

At

The Innovation Drug Discovery, manuscripts are evaluated with the

understanding that they have not been previously published in any form,

either in print or electronic, and are not under consideration by any

other publication or electronic medium. Authors must provide all

in-press or submitted works that are relevant to the manuscript under

consideration by The Innovation Drug Discovery, including those cited in

the manuscript. Additionally, any related manuscripts that have been

submitted elsewhere during the revision process must also be included

with revised manuscripts. Failure to provide copies of related

manuscripts under consideration elsewhere may delay the review process

and may be grounds for rejection.

For more information, please visit https://www.the-innovation.org/innovation-press/policies/editorial-policies/.

Preprint servers

The

Innovation Drug Discovery welcomes submissions of manuscripts that have

previously appeared on recognized preprint servers (e.g., arXiv,

bioRxiv, medRxiv). This policy applies only to the original submitted

version; authors must not post revisions responding to editorial input

or peer review, nor the final published version, on preprint servers.

The journal’s prepublication media policy remains applicable to studies

shared as preprints. For comprehensive guidelines, please refer to the

Innovation Press Self-archiving Policy.

Authorship

Authorship

should be based on substantial intellectual contributions to the work,

in accordance with ICMJE recommendations. Unrestricted joint first or

corresponding authorship is permitted. The corresponding author is

responsible for ensuring all co authors have approved the final

manuscript and for managing communication with the journal. Detailed

criteria, consortia procedures, and authorship change processes are

available in the Innovation Press Editorial Policies (Authorship

section).

Competing interests

All

authors are required to disclose any financial or non financial

interests that may constitute a competing interest. A formal

"Declaration of Interests" form must be completed prior to acceptance,

and a corresponding statement must appear in the manuscript. For further

details, please consult the Innovation Press Editorial Policies

(Declaration of interests section).

Use of AI-assisted technologies in scientific writing

AI

and AI assisted tools may be used solely to improve language and

readability, not to replace core researcher responsibilities such as

data interpretation or drawing scientific conclusions. AI cannot be

listed as an author. Any use of such technologies must be disclosed in a

dedicated “Declaration of AI and AI assisted technologies in the

writing process” section. Complete disclosure instructions are available

in the Innovation Press Open Access Policy (Responsible AI section).

Studies involving humans and animals

Research

involving human participants, human derived materials, or animals must

adhere to all applicable ethical and regulatory standards. Manuscripts

must include statements confirming institutional review board (IRB) or

ethics committee approval, informed consent (where applicable), and

compliance with animal welfare guidelines. Detailed requirements are

provided in the Innovation Press Research Data Policy (Studies involving

humans and animals section).

Distribution of materials and data

The

Innovation Drug Discovery is committed to open and reproducible

research. Authors are expected to make materials, datasets, and code

integral to the study available to qualified researchers under minimal

restrictions. For guidance on data deposition, repository selection, and

data availability statements, please see the Innovation Press Research

Data Policy (Distribution of materials and data section).

Plagiarism prevention

All

manuscripts submitted to The Innovation Drug Discovery are screened for

similarity using iThenticate. Plagiarism, data fabrication, and image

manipulation constitute serious violations of publication ethics.

Suspected misconduct will be investigated in accordance with COPE

guidelines, and consequences may include rejection or retraction. The

full detection process and procedures are described in the Innovation

Press Research Misconduct Policy.

Editorial Process

All

submissions to The Innovation Drug Discovery undergo a thorough

evaluation by the scientific editors to determine their suitability for

publication. Manuscripts that fail to meet the journal's scope or basic

quality standards will be returned to the authors without external

review. Otherwise, manuscripts will be sent to at least two reviewers

who have agreed in advance to assess the paper rapidly.

Peer review progress

The

Innovation Drug Discovery uses a double-blind peer review process, in

which the reviewers' identities are not revealed to the authors. The

editors make every effort to reach decisions on submitted papers within 3

weeks of the submission date. If revisions are necessary, authors are

generally given 4 weeks to make revisions, and only one revised version

of the paper is considered. The significance and conceptual advances of

each submission are evaluated based on the literature available on the

day of final decision, not the day of submission. Accepted papers are

published online ahead of the issue as soon as possible and will appear

in an issue within 2 months of acceptance. Any major changes to accepted

papers are subject to review and may delay publication. The editors and

editorial board members are not involved in decisions about papers that

they have written themselves, that have been written by family members

or colleagues, or that relate to products or services in which the

editor has an interest. Any such submission is subject to all of the

journal’s usual procedures, with peer review handled independently of

the relevant editor and their research groups.

Double-blind peer review protocol

The

Innovation Drug Discovery employs a rigorous double blind peer review

process. To preserve anonymity, authors are required to submit two

separate files: a Title Page (containing author details) and an

Anonymized Manuscript (devoid of any identifying information). Complete

formatting instructions are available in the Innovation Press Editorial

Policies (Double Blind Peer Review Protocol section).

Fast-track review

The

Innovation Drug Discovery offers a Fast-track review process for

manuscripts requiring urgent attention, in addition to its regular

review process. Authors may request this option in their cover letter,

and if granted at the editor's discretion, the manuscript will undergo

an expedited review with a decision made within 1-3 weeks of submission.

The Fast-track process prioritizes manuscripts based on urgency,

potential impact, and the availability of suitable reviewers. Our

extensive network of expert scientist reviewers and streamlined internal

processes provide a solid foundation for prompt peer review

discussions, ensuring we maintain high standards of rigor and fairness

while achieving rapid turnaround times. We are supported by a large and

diverse scientific community, which allows us to quickly identify and

engage the most suitable experts for each submission.

While

not all manuscripts are eligible for Fast-track review, this option

demonstrates our commitment to promptly disseminating crucial findings

while upholding the rigorous standards expected in academic publishing.

The editor's decision on Fast-track eligibility is final, ensuring that

this process is reserved for truly time-sensitive and impactful

research.

......

更多详见：

https://www.the-innovation.org/the-innovation-drug-discovery/authors